Lapatinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lapatinib: A TxGNN-Predicted Signal for Dermatofibrosarcoma Protuberans
One-Sentence Summary
Lapatinib’s original approved indication is not recorded in this evidence pack (the drug currently has no ARTG entries in Australia). The TxGNN model’s top-ranked prediction is Dermatofibrosarcoma Protuberans (DFSP), but this signal is currently supported by zero clinical trials and zero publications — it reflects network-similarity scoring only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (drug is not currently registered in Australia) |
| Predicted New Indication | Dermatofibrosarcoma Protuberans |
| TxGNN Prediction Score | 99.30% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The structured mechanism-of-action field for lapatinib is flagged as a data gap in this evidence pack. However, the rationale text attached to other candidates in this same pack (ranks 2 and 8) consistently references lapatinib’s established mechanism as a dual EGFR/HER2 tyrosine kinase inhibitor, used clinically in HER2-positive breast cancer — this is corroborated evidence within the pack itself, even though it is not captured in the formal MOA field.
Dermatofibrosarcoma protuberans is a soft-tissue sarcoma driven almost exclusively by a COL1A1-PDGFB gene fusion, and its standard targeted therapy is imatinib, a PDGFR inhibitor. This is a distinct signalling pathway from EGFR/HER2. The evidence pack’s own repurposing rationale for this candidate explicitly states there is no known mechanistic relationship between lapatinib’s kinase-inhibition profile and DFSP’s PDGFR-driven biology.
Taken together, this candidate should be read as a TxGNN network-similarity artefact rather than a biologically grounded repurposing hypothesis at this stage. The score (99.30%) is high, but score magnitude alone does not substitute for mechanistic plausibility or empirical support — both of which are currently absent.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
No ARTG entries are recorded for lapatinib in this evidence pack (total licenses: 0). The drug is not currently marketed in Australia under this dataset.
Cytotoxicity
Lapatinib is an antineoplastic agent (referenced in this evidence pack in the context of HER2-positive breast cancer treatment).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (dual EGFR/HER2 tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the Product Information (PI) warnings and precautions |
| Handling Protection | Please refer to the Product Information (PI) warnings and precautions |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (DFSP) has no supporting clinical trials or literature, and the evidence pack itself identifies no plausible mechanistic link between lapatinib’s EGFR/HER2 inhibition and DFSP’s PDGFR-driven pathology. A high TxGNN score alone is insufficient to progress this candidate.
To proceed, the following is needed:
- Confirmed original indication and formal MOA data for lapatinib (currently data gaps)
- TGA/ARTG registration status verification
- Preclinical or mechanistic studies specific to DFSP
- Safety and drug-interaction data (currently unavailable)
Note: Within this same evidence pack, rank 8 (Plasmodium falciparum malaria) carries stronger supporting evidence — L3, in-vitro data showing lapatinib inhibits haemozoin formation — and may warrant separate evaluation as a more mechanistically grounded signal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.